PPBT - PURPLE BIOTECH LTD.
3.18
0 0%
Share volume: 108
Last Updated: Wed 05 Feb 2025 12:00:04 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
1.29%
PREVIOUS CLOSE
CHG
CHG%
$3.18
0.00
0.00%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
-2.15%
1 Month
-29.18%
3 Months
10.42%
6 Months
808.83%
1 Year
302.53%
2 Year
61.63%
Key data
Stock price
$3.18
DAY RANGE
$3.18 - $3.18
52 WEEK RANGE
$0.30 - $13.95
52 WEEK CHANGE
$302.53
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: Gil Efron
Region: US
Website: purple-biotech.com
Employees: 20
IPO year: 2015
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: purple-biotech.com
Employees: 20
IPO year: 2015
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Purple Biotech Ltd. focuses on developing therapies to overcome tumor immune evasion and drug for cancer patients in the United States. Its oncology pipeline includes CM24, a monoclonal antibody that blocks carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors. NT219, a small molecule that targets insulin receptor substrate substrate substrate 1 and 2, and signal transducer and activator of transcription, is in Phase 1/2 clinical trials for the treatment of recurrent and/or metastatic solid tumors.
Recent news